Regulatory Scrutiny and Revised Outlook Weigh on Gerresheimer Shares

German regulator BaFin expands audits into 2024/25 reports as internal control failures force restatements, guidance cuts, and a 33% stock plunge.

Investor confidence in Gerresheimer has been shaken by a confluence of regulatory and operational challenges. The German financial regulator, BaFin, has expanded its ongoing audit of the company's 2024 consolidated financial statements while simultaneously initiating a separate review of the 2025 half-year financial report. This dual-pronged investigation compounds existing pressures from a delayed annual report and a further reduction in the company's financial guidance.

Dual Regulatory Probes and Shareholder Action

On February 25, Gerresheimer disclosed the broadening of BaFin's examination. The 2024 statement review now focuses on potentially misstated lease liabilities and possible omitted impairment charges within the Advanced Technologies division. Concurrently, the new probe into the 2025 half-year report centers on three key areas: a potentially outdated risk reporting system, missing impairment assessments, and incorrectly recognized revenues from bill-and-hold agreements. BaFin auditors have also indicated they possess "concrete evidence" pointing to additional errors in the 2023/24 accounts.

Adding to the corporate governance concerns, the German shareholder association DSW announced it is examining potential claims for damages against the company.

Internal Control Failures Lead to Restatements and Guidance Cut

The publication of the 2025 annual and consolidated financial statements, initially scheduled for February 26, has been postponed. An expanded audit conducted by a second auditing firm revealed "serious deficiencies," primarily concerning the accurate recognition of sales revenue and the valuation of inventory for the 2024 and 2025 fiscal years. Gerresheimer attributes these issues to violations of internal policies and IFRS accounting rules by individual employees.

This follows prior corrections for 2024, where the company identified that €35 million in revenue and €24 million in adjusted EBITDA had been accounted for improperly in relation to bill-and-hold transactions.

Operationally, these developments have forced another downward revision to the company's outlook. Management now anticipates a revenue decline at the lower end of the previously communicated range of -4% to -2% for 2025. Furthermore, the expected EBITDA margin has been reduced from 18.5%-19.0% to a new range of 16.5%-17.5%. The company also forecasts non-cash impairment charges of €220 to €240 million, largely related to its Sensile Medical (Switzerland) and Gerresheimer Moulded Glass Chicago (USA) units.

Market Reaction and Strategic Divestments

Uncertainty is clearly reflected in the market. Shares closed at €16.80 on Friday, representing a 33.39% decline over 30 days and a 39.39% drop since the start of the year. Technical indicators show a 14-day RSI of 17.7 and a high 30-day volatility of 113.05%, consistent with a stock experiencing significant turbulence.

In a strategic move to reduce debt, Gerresheimer has placed two assets on the market: its US subsidiary Centor and its international Moulded Glass business. According to UBS analyst Olivier Calvet, Centor is considered an attractive asset with a stable market position. However, a sale would noticeably alter the group's margin structure, given the unit's above-average profitability.

Critical Path Forward

The immediate calendar is dominated by key deadlines. The timely publication of the annual report by March 31 is viewed as a critical step towards restoring credibility. The next scheduled financial event is the Q1 quarterly statement on April 16, 2026, followed by the Annual General Meeting on June 3, 2026. Until then, the situation will hinge largely on one factor: whether Gerresheimer can conclusively resolve its outstanding accounting issues and provide a coherent explanation for the ongoing regulatory reviews.